Value of Patch Testing in Direct Diet Therapy for Eosinophilic Esophagitis
This trial is active, not recruiting.
|Treatment||allergy patch testing|
|Start date||August 2014|
|End date||June 2017|
|Trial size||8 participants|
|Trial identifier||NCT02227836, 14-002050|
Can allergy patch test (APT) predict of dietary therapy in patients with Eosinophilic Esophagitis?
|Endpoint classification||efficacy study|
|Intervention model||single group assignment|
Reliability of patch testing is defined by the elimination or change of eosinophils in the esophagus with the endoscopic biopsies.
time frame: basesline, six weeks, 10 weeks, 14, weeks, 18 weeks, 20 weeks, 22 weeks, 24 weeks
Male or female participants from 18 years up to 90 years old.
Inclusion criteria: - Adults ages 18-90 - Patients with EoE, defined as dysphagia with histologic finding of greater than or equal to 15 eosinophils per high powered field (eos per HPF) on index esophageal biopsy - Persistent symptoms and/or greater than or equal to 10 eos per HPF on esophageal biopsy after at least 8 weeks of twice daily PPI therapy Exclusion criteria: - Patients with conditions known to be associated with esophageal eosinophilia, including Crohn's disease, Churg-Strauss, achalasia, and hypereosinophilic syndrome - Topical swallowed steroids within 8 weeks of study enrollment - Dermatologic conditions precluding application of Finn chambers to the skin for APT - Inability to read due to: Blindness, cognitive dysfunction, or English language illiteracy
|Official title||Efficacy of Allergy Patch Testing in Directed Dietary Therapy of Eosinophilic Esophagitis: A Pilot Study|
|Principal investigator||Karthik Ravi, MD|
Call for more information